Increased angiogenic activity has been demonstrated in myelofibrosis with myeloid metaplasia (MMM), chronic myeloid leukemia (CML), and essential thrombocythemia (ET) by both bone marrow microvessel density evaluation and measurement of circulating angiogenic factors. MMM is probably the disease with the more pronounced angiogenesis among myeloproliferative disorders but the significance of this finding remains speculative since the angiogenic activity is not correlated with any of the clinical and laboratory features of the disease. Circulating serum levels of angiogenic factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) were found increased in MMM, CML and ET but the frequent thrombocytosis that accompanies these diseases could limit the interpretation of these data since platelets and megakaryocytes may be considered a major source at least for VEGF. However, CML patients treated with interferon were found to have lower VEGF and HGF levels than untreated or hydroxyurea-treated patients, thus suggesting a possible antiangiogenic mechanism of this drug. In addition, preliminary experiences with the antiangiogenic drug thalidomide have shown therapeutic activity in some myeloproliferative disorders.

Keywords:
Angiogenesis, Myelofibrosis, Chronic myeloid leukemia, Essential thrombocythemia, Polycythemia vera
1.
Weidner N, Folkman J: Tumor vascularity as a prognostic factor in cancer; in De Vita VT, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia, Lippincott-Raven, 1996, pp 167–190.
2.
Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J: Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997;150:815–821.
3.
Vacca A, Ribatti D, Presta M, Monischetti M, Iurlaro M, Ria R, Albini A, Bussolino F, Dammacco F: Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999;93:3064–3073.
4.
Thiele J, Rompcik V, Wagner S, Fisher R: Vascular architecture and collagen type IV in primary myelofibrosis and polycythaemia vera: An immunomorphometric study on trephine biopsies of the bone marrow. Br J Haematol 1992;80:227–234.
5.
Lundberg LG, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J: Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol 2000;157:15–19.
6.
Mesa RA, Hanson CA, Rajkumar SV, Schroeder GS, Tefferi A: Evaluation and clinical correlations of microvessel density in myelofibrosis with myeloid metaplasia. Blood 2000;96:3374–3380.
7.
Barosi G: Myelofibrosis with myeloid metaplasia: Diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999;17:2954–2970.
8.
Tefferi A: Myelofibrosis with myeloid metaplasia. N Engl J Med 2000;342:1255–1265.
9.
Dalley A, Smith JM, Reilly JT, Neil SM: Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: Evidence for a role of extracellular calmodulin in fibroblast proliferation. Br J Haematol 1996;93:856–862.
10.
Le Bousse-Kerdiles M-C, Chevillard S, Charpentier A, Romquin N, Clay D, Smadja-Joffe F, Praloran V, Dupriez B, Demory J-L, Jasmin C, Martyre MC: Differential expression of transforming growth factor-β, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood 1996;88:4534–4546.
11.
Martyre M-C, Le Bousse-Kerdiles M-C, Romquin N, Chevillard S, Praloran V, Demory J-L, Dupriez B: Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol 1997;97:441–448.
12.
Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner S, Harris AL, Dirix LY: Quantification of angiogenesis in solid human tumors: An international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996;32A:2474–2484.
13.
Ferrara N, Davis-Smyth T: Biology of vascular endothelial growth factor. Endocr Rev 1997;18:4–25.
14.
Kim J: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vitro. Nature 1993;362:841–844.
15.
Di Raimondo F, Azzaro MP, Palumbo GA, Bagnato S, Stagno F, Giustolisi GM, Cacciola E, Sortino G, Guglielmo P, Giustolisi R: Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia 2001;15:976–980.
16.
Mohle R, Green D, Moore MA, Nachman RL, Rafii S: Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997;94:663–668.
17.
Ziegler BL, Valtieri M, Almeida Porada G, De Maria R, Muller R, Masella B, Gabbianelli M, Casella I, Pelosi E, Bock T, Zanjani ED, Peschle C: KDR receptor: A key marker defining hematopoietic stem cells. Science 1999;285:1553–1558.
18.
Jiang W, Hiscox S, Matsumoto K, Nakamura T: Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implication in cancer. Crit Rev Oncol Hematol 1999;29:209–248.
19.
Thomas DA, Aguayo A, Giles FJ, Albitar M, O’Brien S, Cortes J, Faderl S, Bivins C, Zeldis J, Keating MJ, Barlogie B, Kantarjian MJ: Thalidomide anti-angiogenesis therapy (RX) in Philadelphia (Ph)-negative myeloproliferative disorders (MPD) and myelofibrosis (MF). Blood 1999;94(suppl 1):702a.
20.
Palmblad J, Lerner R, Lundberg LG: Vascular density, intracellular VEGF and bFGF positivity as prognostic factors in polycythemia vera and chronic myelocytic leukemia. Blood 2000;96(suppl 1):257b.
21.
Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O’Brian S, Keating M, Freireich E, Albitar M: Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240–2245.
22.
Ratajczak MZ, Ratajczak J, Machalinski B, Majka M, Marlicz W, Carter A, Pietrzkowski Z, Gewirtz AM: Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor (PLGF) in regulating human haemopoietic cell growth. Br J Haematol 1998;103:969–979.
23.
Janowska-Wieczorek A, Majka M, Pear W, Gewirtz AM, Ratajczak MZ: Chronic myelogenous leukemia (CML) cells stimulate angiogenesis. Blood 2000;96(suppl 1):739a.
24.
Di Raimondo F, Fichera E, Azzaro MP, Stagno F, Palumbo GA, Giustolisi R: Low serum levels of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in IFN-treated chronic myeloid leukemia (CML) patients. Blood 2000;96(suppl 1):253b.
25.
Di Raimondo F, Palumbo GA, Azzaro MP, Giustolisi R: Angiogenesis in acute myeloid leukemia. Blood 2000;96:3656–3659.
26.
Willer A, Hastka J, La Rosee P, Saussele S, Reiter A, Kuhn C, Hochaus A, Hehlmann R: Angiogenesis in chronic myeloproliferative disorders. Blood 2000;96(suppl 1):748a.
27.
Mesa RA, Hanson CA, Li CY, Yoon SY, Schroeder GS, Tefferi A: Bone marrow immunohistochemical features complement histology in distinguishing essential thrombocythemia from reactive thrombocytosis (abstract). Blood 2000;96(suppl 1):3214.
28.
Mesa RA, Li CY, Yoon SY, Schroeder GS, Tefferi A: Clinical correlates of megakaryocyte c-mpl expression in essential thrombocythemia: A clinicopathologic study of 169 patients (abstract). Blood 2000;96(suppl 1):3208.
29.
Wynendaele W, Derua R, Hoylaerts MF, Pawinski A, Waelkens E, de Bruijn EA, Paridaens R, Merlevede W, van Oosterom AT: Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: A key to study an angiogenic marker in vivo? Ann Oncol 1999;10:965–971.
30.
Talks KL, Harris AL: Current status of antiangiogenic factors. Br J Haematol 2000;109:477–489.
31.
Bertolini F, Mancuso P, Gobbi A, Pruneri G: The thin red line: Angiogenesis in normal and malignant hematopoiesis. Exp Hematol 2000;28:993–1000.
32.
Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000;100:57–70.
© 2001 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.